UBS Remains a Hold on Corteva (CTVA)
In a report released today, Joshua Spector from UBS maintained a Hold rating on Corteva, with a price target of $86.00.
Introducing TipRanks MCP for Agents
- Deliver institutional-grade market data directly into Claude, ChatGPT, Cursor, and other MCP-compatible AI tools.
- Designed for personal research, portfolio monitoring, and AI-assisted investment workflows.
Spector covers the Basic Materials sector, focusing on stocks such as Dow Inc, Linde, and LyondellBasell. According to TipRanks, Spector has an average return of 4.3% and a 52.83% success rate on recommended stocks.
Currently, the analyst consensus on Corteva is a Moderate Buy with an average price target of $90.15.
Based on Corteva’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $4.91 billion and a net profit of $720 million. In comparison, last year the company earned a revenue of $4.42 billion and had a net profit of $652 million
Read More on CTVA:
Disclaimer & DisclosureReport an Issue
- Analyst Reiterates Buy on Corteva, Sees Market Underappreciating Growth with Unchanged $95 Price Target
- Corteva price target raised to $95 from $84 at Morgan Stanley
- Corteva headquarters its new companies in Indiana and Iowa
- Corteva price target raised to $90 from $88 at UBS
- Corteva price target raised to $90 from $87 at BofA
